Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sweco expands in Belgium

Sweco is acquiring the operations of HaskoningDHV Belgium after concluding an asset purchase agreement with Royal HaskoningDHV. HaskoningDHV Belgium is specialised in soil investigations and decontamination, environmental impact assessments and integrated area development. This acquisition will further strengthen Sweco’s position on the Belgian market."I am pleased to welcome HaskoningDHV Belgium to Sweco. Sweco has a very solid base in Belgium. We have an efficient organisation and are continuously growing. The experts from HaskoningDHV Belgium are a perfect match for our multidisciplinary

Read original

Capio continues to invest in digital healthcare

Capio is strengthening its involvement in the development of digital healthcare solutions by investing MSEK 49 in the new share issue of MSEK 100 that was announced by the e-health provider Doctrin today. By investing, Capio is participating in the development of new digital applications based on artificial intelligence, increasing efficiency in healthcare provision and improving patient experience.Capio and Doctrin are collaborating since late 2016. During fall this year, implementation of the new digital tools “Better Visits” and “Online Consultations” (Läkarbesök Online) started in Capio’

Yeast can be engineered to create protein pharmaceuticals

It took several years, but a research team headed by Professor Jens Nielsen at Chalmers University of Technology has finally succeeded in mapping out the complex metabolism of yeast cells. The breakthrough, recently published in an article in Nature Communications, means a huge step forward in the potential to more efficiently produce protein therapies for diseases such as cancer. The market for pharmaceuticals that mimic the body’s own proteins – protein-based therapeutics – is exploding. Some of them are relatively simple to manufacture in yeast-based cell factories. Insulin and HPV

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the treatment of melanoma and mesothelioma have successfully passed their respective first, planned, independent safety reviews. These are the first studies to investigate ONCOS-102 in combination with other drugs. The safety reviews of ONCOS-102 in the first four patients in the melanoma trial and first three patients in the mesothelioma trial have been completed without any

Betalutin® shows strong clinical profile in relapsed/refractory indolent NHL and follicular lymphoma

Updated data reported at the 59th Annual American Society of Hematology (ASH) meetingOslo, Norway, 11 December 2017 Nordic Nanovector ASA (OSE: NANO) has presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory (R/R) indolent NHL (iNHL) at the 59th Annual ASH meeting (9-12 December 2017 in Atlanta, GA, USA). A conference call and audio cast to present the results will take place today at 08:00 CET – details below. The updated data continue to highlight Betalutin®’s strong clinical profile

BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting

35 relapsed/refractory AML and MDS patients received BGB324 as monotherapy; two CRi and five PR were observed, and seven patients stayed on treatment for more than four months. Three novel and proprietary predictive biomarker candidates were identified.Bergen, Norway, 11 Dec 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, today announced that it presented an update on the BGBC003 clinical trial (NCT02488408) with selective AXL inhibitor BGB324 in

SEK 4 billion into investment funds in November

In November, investment funds recorded a total net inflow of SEK 4.2 billion. Net deposits were primarily made in bond funds and balanced funds, whereas money market funds and equity funds recorded net withdrawals. The total fund assets in Sweden decreased during the month with SEK 3 billion and amounted at the end of November to SEK 3 993 billion.Investment funds recorded a total net inflow of SEK 4.2 billion in November. Bond funds had net deposits of SEK 3.5 billion and balanced funds had net deposits of SEK 2.9 billion. Money market funds and equity funds, on the other hand, recorded

Starbreeze releases new cinematic trailer for OVERKILL’s the Walking Dead revealing the co-op action shooter’s first character, Aidan

A new cinematic trailer was released today for OVERKILL’s The Walking Dead, the upcoming cooperative first-person shooter in development by OVERKILL – A Starbreeze Studio, together with its partners Skybound Entertainment and 505 Games. This video features Aidan, the first of the game’s four unique playable characters fighting to stay alive in a post-apocalyptic world. Watch the trailer here: https://youtu.be/non_0jlOXew Inspired by the rich story universe of Robert Kirkman’s original graphic novels, OVERKILL’s The Walking Dead is a four-player co-op multiplayer FPS action game set in

Study shows weekly prophylactic treatment with Elocta® resulted in bleed protection and target joint resolution in people with haemophilia A

Swedish Orphan Biovitrum AB (publ)  (Sobi™)(STO:SOBI) and Bioverativ Inc.  (NASDAQ: BIVV) today announce the results of a new, post-hoc, longitudinal analysis of the pivotal Phase 3 A-LONG study and ASPIRE long-term extension study, showing that weekly prophylactic dosing with its extended half-life therapy Elocta® (efmoroctocog alfa) marketed as ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the US, has the potential to provide improved bleed protection over episodic treatment, resolve target joints and reduce the

Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

Stockholm – December 10th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the first survival data were presented at the annual meeting of the American Society of Hematology from the phase II-study O-12-M1 in late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM).Summary of key results presentedThe results show a median progression-free survival (PFS) of 5.7 months, a median overall survival (OS) of 20.7 months and an overall response rate of 31%. The data are very encouraging and compares favorably with other clinical studies in this patient population.

Medivir announces Janssen decision to terminate its simeprevir license effective June 2018

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Pharmaceuticals Inc. (Janssen) has decided to terminate the license that it holds for simeprevir due to Janssen’s assessment of market demand. The termination of the license will become effective in June 2018 and Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time. Medivir will seek to identify potential commercialization partners for specific territories where it believes there may be a market opportunity. Medivir’s

Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

Stockholm – December 9th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that interim data was presented at the American Society of Hematology from the ongoing phase II study HORIZON, treating late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM) that are also refractory to pomalidomide and/or daratumumab.CEO comments on HORIZON“In the HORIZON trial, we are studying Ygalo® in patients that are advanced in their myeloma disease with very poor prognosis and no established treatment options. These patients are suffering from disease progression in conjunction

Stena Line LOVES Freight Drivers This Christmas

As a thank you for Freight Drivers travelling with Stena Line on its Irish Sea North (ISN) routes this festive season, the Irish Sea’s biggest ferry company is giving away £1,000 worth of gift vouchers. The next time you travel with Stena Line ISN just fill in your contact details and post your entry via the box provided in the Truckers Lounge onboard and you could win either a £500 Love2shop voucher or one of five £100 Love2shop vouchers. Best of luck and make sure you get your entry in next time you sail...Rob from CBES has!

Allianz Global Assistance Wins Customer Experience Excellence Award

Allianz Global Assistance USA , a leading provider of travel insurance and assistance, has been named a winner in the sixth annual Customer Experience Excellence Awards.  The annual awards program is managed by Temkin Group, a leading market research, consulting, and training firm that helps organizations accelerate customer experience transformation. The award recognizes companies that are being innovative in their efforts to become more customer-centric. Allianz Global Assistance was recognized for its innovative program to map and review its

STOREBRAND ASA: Capital increase registered in 'Foretaksregisteret'

The capital increase in Storebrand ASA in connenction with the purchase of shares in SKAGEN AS is today registered in 'Foretaksregisteret'. For more detailed information about the transaction, reference is made to the stock exchange announcement published on 25 October 2017. Total share capital in Storebrand ASA is now NOK 2,339,069,910 and there are total 467,813,982 shares. The total number of outstanding shares, adjusted for own shares, are 466,840,310. Lysaker, 8 December 2017 Contact persons/media inquiries: Head of Investor Relations, Kjetil Ramberg Krøkje: kjetil.r.krokje@

Implanting a new workflow

You may not know this interesting dental fact, but the most debilitating oral disorder in the world is edentulism - the state of being partially or without teeth*. Furthermore, 178 million people in the U.S. are missing at least one tooth, and more than 35 million Americans do not have any teeth**! These numbers are projected to grow in the next two decades and point out a growing need for dental implants. Its likely a large percentage of these Americans are seeking to replace lost teeth and to help them dentists require tools to improve implant placement outcome. A surgical Implant guide

DNB ASA - Share buy-back programme finalised

DNB ASA has finalised its share buy-back programme announced on 21 September 2017. A total of 5.4 million shares were repurchased in the open market, whereas a total of 2.7 million shares will be redeemed from the state of Norway, so that its ownership interest in DNB ASA of 34 per cent will remain unaffected following completion of the buy-back programme. The weighted average purchase/redemption price for the 5.4 million shares is NOK 155.75 and with this DNB ASA will return approximately NOK 837 million to shareholders. This is the second share buy-back programme that DNB has finalised

Vitec Software Group AB: Convertible bond fully converted

The convertible bond for Vitec employees with start January 2015 is fully converted. The number of B shares has increased by 442,210, and the share capital increased by SEK 44,221. Total equity has increased by 13,985,736SEK. The total number of shares after conversion amounts to 29,838,900of which 3,350,000are Class A-shares. For more information, please contact Patrik Fransson, Investor Relationspatrik.fransson@vitec.se+46-76-9428597 DisclaimerThis information is of such a kind that Vitec Software Group AB (publ.) is legally required to disclose pursuant to the EU's Market

Chen Man at Fotografiska - a sign of (Chinese) time

Fearless & Fabulous Chen Man at Fotografiska, 9 December – 4 March 2018 The title says it all: Fearless & Fabulous. It takes both courage and magnetic attraction to achieve the position held by Chinese photographer Chen Man. And her success is a significant (Chinese) sign of the time. Chen Man is undoubtedly the pioneer of China’s fashion photographer. Throughout the years, Chen Man has firmly established herself as the most sought-after and certainly the highest paid fashion and portrait photographer in China. Her works have featured across a range of leading publications,

Sandvik has signed an agreement to divest Hyperion

Sandvik has signed an agreement to divest Hyperion to the US listed investment firm KKR at a price of 4 billion SEK. Hyperion delivers advanced wear-resistant tools, applications and components in hard and super-hard materials. Hyperion, with approximately 1,400 employees, has in the last twelve months reported revenues of 3.2 billion SEK, representing 4% of Sandvik’s total revenues. “I’m pleased that we have found a new owner who will support Hyperion’s continued development. This agreement is an important step in focusing Sandvik on its core businesses. The divestment creates

The Danish Eastern High Court revokes the Maritime and Commercial High Court’s decision of 22 February 2016 in favour of Nuevolution’s request

Stockholm, 8 December 2017. After a preliminary court hearing on November 9 and 10, 2017, the Eastern High Court today decided to revoke the Maritime and Commercial High Court’s (Sø- og Handelsretten’s) original decision from February 22, 2016, in favour of Nuevolution’s request, and to send the case back to the Maritime and Commercial High Court for renewed review. Chemgene Holding ApS and Henrik Pedersen was ordered to pay DKK 40,000 excl. VAT to Nuevolution A/S within 14 days. The case will now undergo further written preparation before the Maritime and Commercial High Court, where

RaySearch releases RayStation 7, including support For RayCare integration and Mevion Hyperscan

RayStation® 7*, the latest release of RaySearch’s innovative radiation therapy treatment planning system, adds new functionality and a wide range of improvements. Significant additions include support for HYPERSCAN technology from Mevion Medical Systems, and integration with RayCare*, the next-generation oncology information system shortly to be launched by RaySearch.The functionality additions in the new release are in line with RaySearch’s ambition to unify treatment planning for as many systems as possible, eliminating the complications and additional steps that arise from using multiple

There are no items matching the current filter
There are no more items matching the current filter
Back to top